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Abstract
Background: The emergence of community-associated methicillin-resistant S. aureus was associated with dramatically
increased skin and soft tissue infection (SSTI) incidence in the first few years of the 21st century in the U.S. However,
subsequent trends are poorly understood.
Methods: We examined ambulatory and inpatient data of over 48 million persons years aged 0–64 years from the
HealthCore Integrated Research Database (HIRD) between 2005 and 2010. Data were extracted from medical,
pharmacy, and eligibility databases. We quantified SSTI incidence, type, and complications and comparative
incidence trends for urinary tract infections (UTIs) and pneumonia.
Results: A total of 2,301,803 SSTIs were identified. Most SSTIs (95 %) were treated in the ambulatory setting and
most (60 %) were categorized as abscesses or cellulitis. During the study period, SSTI incidence remained relatively
stable from 47.9 (95 % CI: 47.8–48.1) cases/1,000 PY in 2005 to 48.5 cases/1,000 PY (95 % CI: 48.3–48.6) in 2010).
Persons aged 45–64 years had the highest incidence of both ambulatory-treated and inpatient-treated SSTIs (51.2
(95 % CI: 51.1–51.3) and 3.87 (95 % CI: 3.84–3.90) cases/1,000 PY, respectively). SSTI complications such as myositis,
gangrene, and sepsis occurred in 0.93 % (95 % CI: 0.92–0.94 %) and 16.92 % (95 % CI: 16.87–16.97 %) of
ambulatory-treated and inpatient-treated patients, respectively. SSTI incidence was approximately twice that
of UTIs and tenfold of that of pneumonia.
Conclusions: Among our large, diverse population of persons less than 65 years, SSTI incidence 2005 through
2010 has remained relatively constant at approximately 4.8 SSTIs per 100 person years, suggesting that previously
observed increases in SSTI incidence remain sustained.
Background
Skin and soft tissue infections (SSTIs) are a common
reason to seek medical care in the United States (U.S.),
and worldwide [1, 2]. SSTIs can lead to complications
with significant morbidity, including hospitalization, sur-
gical procedures, bacteremia, and death [3, 4].
Reports from the early 2000s suggest that SSTI inci-
dence in the U.S. was rising. An investigation using data
from the National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey
found that visits for SSTIs to U.S. physician offices, hos-
pital outpatient departments, and emergency depart-
ments increased by 50 % between 1997 and 2004 [1].
U.S. emergency department visits for SSTIs increased
from an estimated 1.2 million visits annually in 1993 to
3.4 million in 2005 [2]. Data from the Healthcare Cost
and Utilization Project National Inpatient Sample (HCUP)
found that hospital admissions for SSTIs increased by
29 % during 2000–2004 [5]. There was no similar rise
noted for other infectious diseases [5].
SSTIs constituted the most rapidly increasing reason for
hospitalizations between 1997 and 2007, with stays for skin
and subcutaneous tissue infections rising 90 % for men
and 75 % for women [6]. Increases in SSTI incidence ap-
pear to be driven by the dramatic increase in community-
associated methicillin-resistant Staphylococcus aureus
(CA-MRSA) skin infections [1, 2, 5]. However, since this
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time there are few subsequent data on whether incidence
of SSTIs in both ambulatory and inpatient settings has
peaked, stabilized, or continued to rise. Additionally, there
are no investigations that have taken a holistic approach to
quantifying SSTI incidence in both the ambulatory and
inpatient settings. To better understand trends in SSTI
incidence, we reviewed administrative claims data within a
large database of commercially insured members, who
have full medical and pharmacy eligibility.
Methods
We performed an observational retrospective cohort
study utilizing administrative claims data. Data included
medical and pharmacy claims from the HealthCore
Integrated Research Database (HIRD). The HIRD data
environment includes linked medical, pharmacy, and
eligibility data from 14 health plans in the US, and in-
cludes health maintenance, point-of-service, preferred
provider organizations and indemnity plans located in
the northeastern, southeastern, mid-Atlantic, Midwest-
ern, and western regions of the US. Data from the
HIRD has been used previously in multiple incidence
and cost studies [7–10] and includes information on
over 48 million person years from 2005 to 2010.
For purposes of this analysis, we included all persons
with at least one day of enrollment within the health
plan. All data were handled in compliance with the
Health Insurance Portability and Accountability Act
(HIPAA) of 1996, and a limited dataset was used for the
analyses. The limited dataset contained the fields of
interest specific to the study including eligibility, med-
ical and pharmacy information for the specified cohort
during the study period and limits the amount of pro-
tected health information (PHI) in the dataset. Due to
the fact that this research is observational in nature,
with no intervention conducted on human subjects, and
the research involves the analysis of existing administra-
tive claims data, which is accessible by the investigators
in such a manner that subjects cannot be identified,
directly or through identifiers linked to the subjects, the
study was approved as an exempt investigation by the
Institutional Review Board at the Los Angeles Biomed-
ical Research Institute at Harbor-UCLA.
SSTI incidence rates were obtained from the overall
HIRD population. To calculate incidence, all SSTI epi-
sodes from 01/01/2005 through 12/31/2010 were in-
cluded. Patient selection was defined as patients who
had ≥1 medical (inpatient, emergency room [ER] or
outpatient) claim with an ICD-9 diagnosis code for an
SSTI between 01/01/2005 and 12/31/2010. The earliest
occurrence was defined as the onset date for the first
(index) SSTI episode. Any two consecutive claims for
SSTIs or their complications within 30 days of each
other were considered part of the same SSTI episode. A
new SSTI episode therefore occurred if a SSTI claim was
preceded by at least 31 days without any claim for SSTI or
complication. Second, incidence rates were then calcu-
lated by dividing the number of all SSTIs during the study
period by the person-years (PY) contributed by each
member during the calendar year. To assess whether po-
tentially observed trends in SSTI were related to changes
in the HIRD population or our methodology, we assessed
annual incidence of two common infections occurring in
the ambulatory and inpatient settings, pneumonia and
urinary tract infections (UTIs) from 2005 to 2010, for
which we hypothesized there would be no significant
changes in infection incidence.
ICD-9 codes for SSTIs (Table 1) were identified
based on definitions from previous investigations util-
izing administrative claims data for identification of
SSTIs [1, 2, 4, 5]. If an SSTI episode had claims with
multiple clinical diagnoses for SSTIs, a hierarchy was
implemented to categorize the type of SSTI episode
and the infection was categorized as the more severe
infection. The following categorization hierarchy, based
on clinical judgment, was used (starting with most se-
vere): (1) infection due to device or graft; (2) surgical site
infection; (3) non-healing surgical wound; (4) decubitus
ulcer; (5) mastitis; (6) cellulitis/abscess; (7) erysipelas; (8)
other skin and soft tissue infections; (9) furuncle/carbun-
cle; (10) impetigo; and (11) folliculitis. We also used ICD-
9 codes to identify pneumonias (481.xx, 482.xx, 483.xx,
485.xx and 486.xx) and UTIs (590.xx and 599.0) employ-
ing the same rules for SSTI claims outlined above, in
which claims within 30 days of each other were consid-
ered to be part of the same episode. ICD-9 codes were
based on pneumonia and UTI definitions from previous
investigations utilizing administrative claims data [11–13].
Because of limitations of the HIRD extraction process, we
used data on pneumonia and UTIs from 2005 to 2009.
Classification of SSTI episodes
Ambulatory-treatment vs. inpatient-treated of SSTI
SSTI episodes were classified as ambulatory-treated or
inpatient-treated depending on where the first claim of
the infection episode occurred. SSTIs whose first claim
occured in the ambulatory care setting but resulted in a
hospitalization were considered to be inpatient-treated.
For ambulatory-treated infections, the proportion of
episodes with a hospitalization was calculated. Further,
any inpatient stay containing a clinical diagnosis of SSTI
or its complications as one of the hospital discharge
diagnoses during the infection episode was also cap-
tured. For inpatient-treated infections, we calculated re-
hospitalization rates as the proportion of infections that
had a subsequent hospitalization related to SSTI or its
complications during the infection episode.
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Complicated SSTIs vs. uncomplicated SSTIs
All SSTI episodes were categorized as either complicated
or uncomplicated, based upon prior definitions [14, 15]
in which complicated SSTIs were defined as a ICD-9
code diagnoses of severe SSTI or by the presence of a
significant comorbid condition. Categories of severe
SSTI diagnoses are detailed in Table 1. Comorbid condi-
tions present during the pre-index period made any
SSTI a complicated infection. These conditions included
(a) chronic kidney disease; (b) chronic liver disease; (c)
alcohol or drug abuse; (d) peripheral artery disease; (e)
neuropathy; (f ) diabetes; (g) obesity; and (h) compro-
mised immune system (see Table 1 for ICD-9 codes).
Complications of SSTI episodes
Further, we examined relatively commonly described
SSTI complications or sequelae [15]. These complica-
tions included lymphadenitis (ICD-9: 683.xx); myositis
(ICD-9: 728.0x); necrotizing fasciitis (ICD-9: 728.86);
gangrene (ICD-9: 040.0x, 785.4x); osteomyelitis (ICD-
9:730.xx); bacteremia (ICD-9:790.7x); endocarditis (ICD-
9:391.1x); and septicemia or sepsis (ICD-9: 038.x, 040.82,
785.52). An SSTI occurrence was considered to have a
complication if the complication occurred during the
infection episode. Based on clinical experience, osteo-
myelitis was flagged as associated with an SSTI if it was
preceded by an SSTI claim within 90 days.
Statistical comparisons were made using the chi-
squared test and Cochrane-Armitage test, as appropriate.
All analyses were performed using SAS 9.2 (Cary, North
Carolina). A p value of p < 0.05 was considered to be sta-
tistically significant.
Results
There were a total of 2,301,803 SSTIs in both the ambu-
latory and inpatient settings between 2005 and 2010.
The vast majority (95 %) of SSTIs were diagnosed in the
outpatient setting (ambulatory-treated; 45.73, 95 % con-
fidence interval (CI): 45.67–45.79 episodes per 1,000 PY)
vs. 2.19 (95 % CI: 2.17–2.20) episodes per 1,000 PY that
were inpatient-treated (Table 2).
The age group with the highest incidence of SSTIs
was 45–64 years in both the ambulatory-treated (51.23
SSTIs per 1,000 PY, 95 % CI: 51.12–51.34) and the
inpatient-treated SSTIs (3.87 SSTIs per 1,000 PY, 95 %
CI: 3.84–3.90; Table 2). In the ambulatory-treated SSTIs,
differences in SSTI incidence were relatively modest be-
tween this group and the younger age groups; SSTI inci-
dence among those ages 0–17 years and 18–44 years
was 43.51 (95 % CI: 43.40–43.63) and 42.85 (95 % CI:
42.77–42.94) SSTIs per 1,000 PY, respectively. However,
among inpatient-treated SSTIs, incidence differences
were more pronounced. Incidence was 0.91 (95 % CI:
0.89–0.93) and 1.64 (95 % CI: 1.62–1.65) SSTIs per
1,000 PY among those ages 0–17 and 18–44, respect-
ively, compared to 3.87 (95 % CI: 3.84–3.90) SSTIs per
1,000 PY among those age 45–64 (p < 0.0001).
The clinical diagnosis of abscess or cellulitis was the
most common SSTI, representing 57.32 % (95 % CI:
57.26–57.38 %) of SSTIs overall; 57.62 % (95 % CI:
59.90–60.03) in the ambulatory-treated and 51.13 %
(95 % CI: 50.71–51.55) in the inpatient-treated groups
(Table 3). The remaining cases of SSTIs (ambulatory
Table 1 Skin and soft tissue infections (SSTI) by clinical
condition, severity, and ICD-9 code
Description ICD-9 codes
Uncomplicated SSTI
Carbuncle and furuncle 680.x











Infection due to device or
graft
996.6x




Any SSTI diagnosis in a
patient with any of the
following comorbidities:
Diabetes 250.xx
Chronic kidney disease 585.xx, 403.xx
Chronic liver disease 571.xx, 572.xx
Peripheral artery disease 440.xx, 443.9
Neuropathy 356.xx, 357.xx, 250.6x
Obesity 278.0x, 278.00, 278.01, 278.02, V85.21,
V85.22, V85.23, V85.24, V85.25, V85.4,
V85.3x
Alcohol or drug abuse 303.xx, 304.xx, 305.xx
Compromised immune
function
279.0x, 279.1x, 279.2x, 279.3x, 334.8x
aCellulitis, erysipelas, and folliculitis were considered complicated if the index
diagnosis of the primary diagnosis was on an inpatient claim
bDecubitis ulcer and non-healing surgical wound were considered an
active infection if: either a) clinical diagnosis was associated with concomitant
prescription of any of the following of antibiotics: dicloxacillin, vancomycin,
cefalexin, cefazolin, linezolid, daptomycin, clindamycin, trimethoprim-
sulfamethoxazole, doxycycline, minocycline, quniupristin-dalfopristin within ±
10 days of the index diagnosis; or b) if no other concomitant clinical diagnosed
infection occurred
Uncomplicated and complicated categories adapted from: Stevens DL
et al. [15]
Miller et al. BMC Infectious Diseases  (2015) 15:362 Page 3 of 8
and inpatient combined) were comprised of folliculitis
(12.00 %, 95 % CI: 11.96–12.04 %)), impetigo (6.61 %,
95 % CI: 6.58–6.64 %)), furuncle (3.29 %, 95 % CI:
3.26–3.31 %)), mastitis (2.25 %, 95 % CI: 2.23–2.27 %)),
surgical site infection (2.19 %, 95 % CI: 2.17–2.21 %)),
decubitus ulcer (5.28 %, 95 % CI: 5.25–5.31 %)), device
or graft (1.21 %, 95 % CI: 1.19–1.22 %)) and other (un-
specified cases of SSTI; 9.25 %, 95 % CI: 9.21–9.29 %)).
Distributions of SSTI type stratified by ambulatory-
treated and inpatient-treated SSTIs are further outlined
in Table 3.
For inpatient-treated SSTIs, several categories of SSTIs
had higher proportion of diagnosis than compared to their
proportion in the ambulatory-treated group. These cat-
egories included surgical site infections (19.86 %, 95 % CI:
19.81–19.91 %)), SSTIs associated with devices or grafts
(12.58 %, 95 % CI: 12.54–12.62 %)) and decubitus ulcers
(9.66 %, 95 % CI: 9.62–9.70 %), p < 0.0001 for all compari-
sons) (Table 3). Overall, rates of complications of SSTIs
including lymphadenitis, myositis, necrotizing fasciitis,
gangrene, osteomyelitis, bacteremia, endocarditis, septi-
cemia and sepsis, were 1.16 % (95 % CI: 1.15–1.17 %) in
the outpatient-treated SSTIs and 23.28 % (95 % CI:
23.02–23.54 %) in the inpatient-treated SSTIs (Table 3).
Additional complications of SSTIs and proportion pa-
tients of re-hospitalized stratified by initial SSTI cat-
egory and treatment location are detailed in Table 3.
Temporal trends in SSTIs are summarized in Fig. 1.
Despite a slight decrease from 2005 to 2007, SSTI inci-
dence remained relatively unchanged from 2005 to
2010, from 47.94 (95 % CI: 47.79–48.09) to 48.46 (95 %
CI: 48.31–48.61) SSTIs per 1,000 PY. In this time
period, the incidence of uncomplicated SSTIs also
remained relatively stable from 27.34 (95 % CI: 27.23–
27.46) to 27.45 (95 % CI: 27.33–27.57) SSTIs per 1,000
PY, as did complicated infections 20.57 (95 % CI:
20.47–20.67) to 20.99, (95 % CI: 20.88–21.09) SSTIs/
1,000 PY. Although all trends were statistically signifi-
cant (p < 0.0001 for all comparisons), the magnitude of
change was relatively small.
In our comparative examination of other common in-
fectious diseases from 2005 to 09, we found an incidence
of UTIs, ranging from 17.31 to 19.95 infections per
1,000 PY during the study period, and incidence of
pneumonia ranging from 4.59 to 5.03 per 1,000 PY dur-
ing the study period (Fig. 2).
Discussion
We performed an examination of both ambulatory- and
inpatient-treated SSTIs as part of a single investigation
in a large cohort of patients. We analyzed data from an
administrative database and identified over 2.3 million
SSTIs between 2005 and 2010. We found that the inci-
dence of SSTIs is substantial and approximately twice of
that of UTIs and tenfold of that of pneumonia. In our
study period, on average, over 4 SSTIs occurred per 100
persons aged 0–64 years old annually. We also found
that SSTIs were about twenty times more likely to be
ambulatory-treated than inpatient-treated. Finally, our
findings suggest that the rapid increase in SSTI inci-
dence observed earlier during this Century [1, 2, 5] has
leveled off, and SSTI incidence has been relatively stable
across our study period.
We used ICD-9 codes to identify SSTI occurrences,
which is a research identification method similar (or
identical) to previous SSTI investigations [1, 2, 5]. While
diagnosing SSTIs using ICD-9 coding has limitations
(i.e., potential misclassification, coding errors), we ob-
served that our SSTI incidence was comparable to other
studies that used different administrative claims data-
bases. Hersch et al. estimated outpatient infections in
the U.S. and found that the visit rate among patients
Table 2 Incidence rate of skin and soft tissue infections (SSTIs) by initial location of treatment and age group from 2005 through
2010
Initial location of treatment SSTI cases Person- years (PY)a SSTI cases / 1,000 PY 95 % Confidence interval
Lower Upper
Ambulatory setting
0–17 years 500,434 11,500,647 43.51 43.40 43.63
18–44 years 898,215 20,960,045 42.85 42.77 42.94
45–64 years 798,182 15,579,211 51.23 51.12 51.34
0–64 years 2,196,831 48,039,902 45.73 45.67 45.79
Inpatient setting
0–17 years 10,444 11,500,647 0.91 0.89 0.93
18–44 years 34,299 20,960,045 1.64 1.62 1.65
45–64 years 60,229 15,579,211 3.87 3.84 3.90
0–64 years 104,972 48,039,902 2.19 2.17 2.20
aAfter discounting episode duration
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aged 18–44 years increased from 13.1 visits per 1,000
population in 1997 to 27.1 in 2005 [1]. Their 2005 esti-
mates compare to our findings of 42.9 ambulatory-
treated infections per 1,000 population per year between
2005 and 2010 in this age group. However, they used data
from the National Ambulatory Medical Care Survey,
which did not sample non-physician clinician visits in
office-based practices, which may in part explain their
lower incidence [16]. Edelsberg et al. found that an esti-
mated 289,715 admissions occurred for SSTIs among
patients aged 45–64 years in 2004 [5]. Our estimate of
SSTIs with inpatient-treated of 3.9 per 1,000 PY in the
45–64 age category represents about 277,000 episodes
during 2004, based on U.S. census population estimates
for this year [17]. These results suggest that our findings
of SSTI incidence are valid in comparison to other investi-
gations employing claim-based methodologies. Finally,
our SSTI incidence over the study period of 47.9 SSTIs/
1000 person years is also similar to that the 49.6 SSTIs/
1000 person year rate found in a population of Kaiser Per-
manente Northern California patients from 2009 to 2011
when analyzing electronic medical records and adminis-
trative databases [18].
Our study is novel as it compares SSTI incidence to
other common infectious diseases. The reasons for
these comparisons were twofold. First, if a trend was
noted SSTI incidence, we wanted to ensure that these
represented true incidence changes rather than secular
changes in the HIRD population or other methodo-
logical factors. However, SSTI incidence changes















Abscess/Cellulitisc 1,265,736 57.62 % 0.93 % 0.14 % 0.03 % 0.08 % 0.46 % 0.31 %
Folliculitis 275,751 12.55 % 0.22 % 0.08 % 0.00 % 0.01 % 0.02 % 0.11 %
Impetigo 151,856 6.91 % 0.28 % 0.14 % 0.01 % 0.00 % 0.01 % 0.13 %
Furuncle 75,280 3.43 % 0.56 % 0.14 % 0.02 % 0.03 % 0.08 % 0.31 %
Mastitis 50,262 2.29 % 0.28 % 0.05 % 0.01 % 0.02 % 0.04 % 0.17 %
Surgical Site Infection 29,520 1.34 % 4.23 % 0.09 % 0.09 % 0.21 % 2.34 % 1.89 %
Decubitus Ulcer 111,320 5.07 % 6.77 % 0.02 % 0.13 % 1.47 % 5.06 % 1.67 %
Device or Graft 14,534 0.66 % 8.59 % 0.04 % 0.05 % 0.16 % 3.52 % 5.29 %
Non-healing Surgical
Wound
12,159 0.55 % 4.69 % 0.05 % 0.26 % 0.87 % 2.32 % 1.71 %
Other 210,413 9.58 % 0.75 % 0.07 % 0.02 % 0.05 % 0.43 % 0.21 %
All 2,196,831 100.0 % 1.16 % 0.11 % 0.03 % 0.14 % 0.64 % 0.39 %
In inpatient settings
Abscess/Cellulitisc 53,667 51.13 % 16.92 % 1.10 % 1.47 % 1.90 % 5.03 % 10.77 %
Folliculitis 528 0.50 % 7.77 % 0.00 % 0.00 % 0.19 % 0.95 % 7.20 %
Impetigo 310 0.30 % 8.06 % 0.00 % 0.65 % 0.32 % 0.97 % 6.45 %
Furuncle 363 0.35 % 13.77 % 0.28 % 0.83 % 1.93 % 3.31 % 10.19 %
Mastitis 1,533 1.46 % 6.07 % 0.13 % 0.20 % 0.33 % 0.33 % 5.28 %
Surgical Site Infection 20,849 19.86 % 23.86 % 0.12 % 0.59 % 0.77 % 6.05 % 18.78 %
Decubitus Ulcer 10,140 9.66 % 35.12 % 0.07 % 1.16 % 9.67 % 18.19 % 18.29 %
Device or Graft 13,204 12.58 % 44.21 % 0.07 % 0.23 % 0.73 % 8.58 % 37.73 %
Non-healing Surgical
Wound
1,861 1.77 % 18.27 % 0.05 % 1.18 % 3.44 % 6.34 % 10.21 %
Other 2,517 2.40 % 17.40 % 0.24 % 1.03 % 2.54 % 7.47 % 9.81 %
All 104,972 100.01 % 23.28 % 0.61 % 1.07 % 2.29 % 6.92 % 16.33 %
aComplications are not mutually exclusive
b Any inpatient occurrence with an SSTI diagnosis or SSTI complication following the index date
cAbscess/cellulitis category includes erysipelas (1,035 in ambulatory settings and 78 in inpatient settings)
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observed were relatively modest and likely represented
year to year fluctuations rather than true trends ob-
served between the late 1990s and 2005 in other popu-
lations [1, 2, 5]. The second reason for comparing
SSTI trends to other common infectious diseases is
descriptive. We chose pneumonia and UTIs given they
are relatively common infections seen in both inpatient
and ambulatory settings and affect both children and
adults. We found an SSTI incidence approximately twice
of that of UTIs and 10 fold of that of pneumonia. The
UTI incidence of 17.3–20.0 UTIs per 1,000 PY is compar-
able to findings from outpatients <65 years in Veteran
Fig. 1 Incidence of skin and soft tissue infections (SSTIs) by severity from 2005 through 2010. Note: 95 % confidence interval bars are not
included, as the confidence intervals very narrow and would not be visible in the figure
Fig. 2 Incidence of skin and soft tissue infections (SSTIs), pneumonia and urinary tract infections (UTIs) from 2005 through 2010. Abbreviations:
SSTI = Skin and Soft Tissue infection; UTI = Urinary Tract Infection. Note: 95 % confidence interval bars are not included, as the confidence intervals
very narrow and would not be visible in the figure
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Administration (VA) clinics in 2001. Among females, our
UTI incidence was 31.43 UTIs/1,000 PY (data not shown),
which is comparable to the estimated 55.1–60.6 UTIs per
1,000 PY in VA clinics [11]. Among males, UTI incidence
was 5.23 UTIs/1,000 PY (data not shown), which is com-
parable to the estimated 16.7–22.7 UTIs per 1,000 PY
men [12]. Our lower rate may be related to the fact that
the VA does not care for children, in which the incidence
of UTI is very low [11, 12], and the VA population may
not be representative of insured adults. When these facts
are considered, the rates may be more comparable. Our
pneumonia incidence we found was comparable to ICD-9
code data from the very large MarketScan Commercial
database, in which the pneumonia incidence of 4.89 epi-
sodes per 1,000 PY among those aged 18–64 [13] is com-
parable to our incidence of 4.10–5.03 per 1,000 PY.
Our study has several strengths. First, we studied
trends in a demographically diverse population that in-
cluded a very large group of persons with and without
significant co-morbidities. Second, the time period of
our investigation was novel in that it examined SSTI
incidence in the period after a rapid rise in SSTIs that
occurred in the first 5 years of the 21st Century [1, 2].
Third, we used databases that included both inpatient
and outpatient treated SSTIs. Previous large studies in
the U.S. captured skin infections only in ambulatory set-
tings, and used sample sizes that were a thousand-fold
smaller than the present research to create estimates of
SSTI [1, 19]. SSTI investigations in hospitalized patients
that used HCUP data utilized a stratified random sample
of only inpatient stays for SSTI [5, 6]. Unlike these pre-
vious efforts, our investigation directly measured SSTI
rates rather than analyzing a subset of cases or a con-
venience sample.
There are limitations to our investigation. First, due to
the nature of the commercially insured data used, we
did not include persons over 65, the majority of them
who utilize a Medicare or fee-for-service reimbursement
model instead of commercial insurance plans. If we were
able to quantify SSTI incidence in older Americans, it is
likely the rates of infection would be substantially higher
in this age group compared to younger persons. Older
Americans typically have a higher prevalence of co-
morbidities associated with increased risk for SSTI [20]
and they have a higher risk of many other infections
probably due co-morbidities and declines in host de-
fenses [21, 22]. Second, we did not have microbiologic
correlations for each SSTI. Thus we could not assess if
the relationship between CA-MRSA trends and SSTI
incidence in our cohort. Nevertheless, other investiga-
tions have shown that CA-MRSA appears to be the pri-
mary cause of increasing community-associated SSTI
incidence in the beginning around 2000 [23, 24]. Third,
although we were able to categorize diagnoses of skin
infection by clinical type, the accuracy of these designa-
tions is unclear as diagnoses were derived from billing
codes that may or may not have reflected accurately the
pathology of the actual infection seen by clinician.
Fourth, our designation of uncomplicated and compli-
cated may not necessarily be consistent with defini-
tions used by others [14, 15]. Regardless, there is no
standardized definition distinguishing complicated
from uncomplicated infection and, when developed,
such distinctions may only be useful for clinical trials
in which clinicians are prospectively determining defi-
nitions based on clinical presentation [25]. Finally, our
study population is selected from all the U.S. regions
and some regions are more represented than others.
However, overall the HIRD population is geographic-
ally diverse and covers most regions of the U.S.
Conclusion
In summary, we found that SSTI incidence between 2005
and 2010 has remained relatively constant, suggesting that
with previously observed increases in SSTI incidence have
now been stabilized. The SSTI incidence remained rela-
tively steady among both ambulatory-treated and inpatient-
treated infections as well as among both complicated and
uncomplicated infections. Between 2005 and 2010, approxi-
mately 4.8 SSTIs requiring medical attention annually oc-
curred per 100 person years among those aged 64 years
and younger. Given the high incidence of SSTIs, interven-
tions to prevent SSTIs would have great potential to reduce
disease morbidity and health care utilization.
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